X-linked Hypophosphatemia
📧 Sign up to get email alerts when something new happens for X-linked Hypophosphatemia.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2020-06-18FDA Approved: CRYSVITA — Supplemental Application (Kyowa Kirin, Inc.)
The FDA approved a supplemental application for CRYSVITA (burosumab) submitted by Kyowa Kirin, Inc.
-
CLINICAL_TRIALS trial_result · 2020-06-05Clinical Trial Update: Burosumab in Children and Adolescents With X-linked Hypophosphatemia [Phase 4]
Phase 4 clinical trial update for burosumab in children and adolescents with X-linked hypophosphatemia (XLH).
-
CLINICAL_TRIALS trial_result · 2019-12-16Clinical Trial Update: Long-Term Extension Study of KRN23 in Adult Subjects With X-Linked Hypophosphatemia (XLH) [Phase 2]
Phase 2 long-term extension trial of KRN23 (burosumab) in adults with X-Linked Hypophosphatemia has completed; results were posted in 2019.
-
CLINICAL_TRIALS trial_result · 2019-05-22Clinical Trial Update: Study of KRN23 (Burosumab), a Recombinant Fully Human Monoclonal Antibody Against Fibroblast Growth Factor 23 (FGF23), in Pediatric Subjects With X-linked Hypophosphatemia (XLH) [Phase 2]
Phase 2 study of burosumab (KRN23) in pediatric X-linked hypophosphatemia completed; results posted evaluating safety and efficacy.
-
CLINICAL_TRIALS trial_result · 2019-04-11Clinical Trial Update: Efficacy and Safety of Burosumab Versus Oral Phosphate and Active Vitamin D Treatment in Pediatric Patients With XLH [Phase 3]
Phase 3 trial comparing burosumab to oral phosphate and active vitamin D in pediatric patients with X-linked hypophosphatemia; results asses…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2019-01-30Clinical Trial Update: Using Different Doses of Active Vitamin D Combined With Neutral Phosphate in Children With X-linked Hypophosphatemia [Phase 4]
Phase 4 trial evaluating different doses of active vitamin D with neutral phosphate in children with X-linked hypophosphatemia.
-
CLINICAL_TRIALS trial_result · 2018-09-25Clinical Trial Update: Open Label Study of KRN23 on Osteomalacia in Adults With X-linked Hypophosphatemia (XLH) [Phase 3]
Open-label Phase 3 study evaluating KRN23 for osteomalacia in adults with X-linked hypophosphatemia completed; results were posted in 2018.
-
CLINICAL_TRIALS trial_result · 2018-06-19Clinical Trial Update: Study of the Safety, Pharmacodynamics (PD) and Efficacy of KRN23 in Children From 1 to 4 Years Old With X-linked Hypophosphatemia (XLH) [Phase 2]
Phase 2 study evaluating safety, pharmacodynamics, and efficacy of KRN23 in children aged 1 to 4 with X-linked hypophosphatemia; the trial i…
-
FDA approval · 2018-04-17FDA Approved: CRYSVITA — Original Application (Kyowa Kirin, Inc.)
FDA approved CRYSVITA (burosumab) from Kyowa Kirin as the original application for the treatment of X-linked hypophosphatemia.
-
CLINICAL_TRIALS trial_result · 2017-05-31Clinical Trial Update: Calcitonin for Treating X-linked Hypophosphatemia [NA]
A Yale University-sponsored clinical trial evaluating calcitonin for the treatment of X-linked hypophosphatemia has completed and posted res…
-
CLINICAL_TRIALS trial_result · 2017-03-03Clinical Trial Update: A Study of KRN23 in Subjects With X-linked Hypophosphatemic Rickets/Osteomalacia [Phase 1]
Phase 1 study of KRN23 in X-linked hypophosphatemia with osteomalacia has completed.